174 related articles for article (PubMed ID: 37266697)
1. Outcomes of Patients with an Intermediate-Risk Group According to the Japanese Risk Classification of Papillary Thyroid Carcinoma.
Horiuchi K; Fujimoto M; Hidenori K; Yoshida Y; Noguchi E; Omi Y; Okamoto T
World J Surg; 2023 Oct; 47(10):2464-2473. PubMed ID: 37266697
[TBL] [Abstract][Full Text] [Related]
2. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
3. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
4. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
[TBL] [Abstract][Full Text] [Related]
5. Is Postoperative Adjuvant Radioactive Iodine Ablation Therapy Always Necessary for Intermediate-Risk Papillary Thyroid Cancer Patients With Central Neck Metastasis?
Han K; Noh HM; Jeong HM; Lim YC
Ann Surg Oncol; 2021 Nov; 28(12):7533-7544. PubMed ID: 34043093
[TBL] [Abstract][Full Text] [Related]
6. Higher adjuvant radioactive iodine therapy dosage helps intermediate-risk papillary thyroid carcinoma patients achieve better therapeutic effect.
Li X; Zheng H; Ma C; Ji Y; Wang X; Sun D; Meng Z; Zheng W
Front Endocrinol (Lausanne); 2023; 14():1307325. PubMed ID: 38298190
[TBL] [Abstract][Full Text] [Related]
7. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer.
Sohn SY; Choi JY; Jang HW; Kim HJ; Jin SM; Kim SW; Suh S; Hur KY; Kim JH; Chung JH; Kim SW
Thyroid; 2013 Jun; 23(6):741-7. PubMed ID: 23205883
[TBL] [Abstract][Full Text] [Related]
8. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan M; Perkins JM; Roman SA; Sosa JA
J Clin Endocrinol Metab; 2015 Apr; 100(4):1529-36. PubMed ID: 25642591
[TBL] [Abstract][Full Text] [Related]
10. Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma.
Suman P; Wang CH; Moo-Young TA; Prinz RA; Winchester DJ
Am Surg; 2016 Sep; 82(9):807-14. PubMed ID: 27670568
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for radioactive iodine-avid metastatic lymph nodes on post I-131 ablation SPECT/CT in low- or intermediate-risk groups of papillary thyroid cancer.
Lee CH; Jung JH; Son SH; Hong CM; Jeong JH; Jeong SY; Lee SW; Lee J; Ahn BC
PLoS One; 2018; 13(8):e0202644. PubMed ID: 30118516
[TBL] [Abstract][Full Text] [Related]
12. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
[TBL] [Abstract][Full Text] [Related]
13. Radioactive iodine in low- to intermediate-risk papillary thyroid cancer.
Zhao H; Gong Y
Front Endocrinol (Lausanne); 2022; 13():960682. PubMed ID: 36034423
[TBL] [Abstract][Full Text] [Related]
14. Impact of radioiodine therapy on recurrence and survival outcomes in intermediate-risk papillary thyroid carcinoma -A systematic review and meta-analysis.
Chandekar KR; Satapathy S; Bal C
Clin Endocrinol (Oxf); 2024 Feb; 100(2):181-191. PubMed ID: 38050454
[TBL] [Abstract][Full Text] [Related]
15. Five-Year Oncologic Outcome and Surgical Completeness of Transoral Robotic Thyroidectomy for Papillary Thyroid Carcinoma: Comparison with Conventional Transcervical Thyroidectomy Using Propensity Score Matching.
Lee SJ; Ryu SR; Ji YB; Song CM; Park JH; Kim DS; Tae K
Ann Surg Oncol; 2023 Apr; 30(4):2256-2264. PubMed ID: 36602660
[TBL] [Abstract][Full Text] [Related]
16. Factors Affecting Ablation Success After I-131 Radioactive Iodine Therapy in Low and Intermediate Risk Papillary Thyroid Cancer.
Goksel S; Avci U
Horm Metab Res; 2023 Oct; 55(10):677-683. PubMed ID: 37267999
[TBL] [Abstract][Full Text] [Related]
17. The impact of socioeconomic status on the use of adjuvant radioactive iodine for papillary thyroid cancer.
Zevallos JP; Xu L; Yiu Y
Thyroid; 2014 Apr; 24(4):758-63. PubMed ID: 24378070
[TBL] [Abstract][Full Text] [Related]
18. Effect of Radioactive Iodine Therapy on Cancer-Specific Survival of Papillary Thyroid Cancer Tall Cell Variant.
Dai P; Zhao W; Zheng X; Luo H; Wang X
J Clin Endocrinol Metab; 2024 Feb; 109(3):e1260-e1266. PubMed ID: 37804527
[TBL] [Abstract][Full Text] [Related]
19. TIMING OF RADIOACTIVE IODINE THERAPY DOES NOT IMPACT OVERALL SURVIVAL IN HIGH-RISK PAPILLARY THYROID CARCINOMA.
Suman P; Wang CH; Abadin SS; Block R; Raghavan V; Moo-Young TA; Prinz RA; Winchester DJ
Endocr Pract; 2016 Jul; 22(7):822-31. PubMed ID: 27018620
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Papillary Thyroid Microcarcinoma Presenting with Palpable Lateral Lymphadenopathy.
Papachristos A; Do K; Tsang VH; Sywak M; Gill AJ; Sidhu S; Clifton-Bligh RJ; Glover A; Gild ML
Thyroid; 2022 Sep; 32(9):1086-1093. PubMed ID: 35703333
[No Abstract] [Full Text] [Related]
[Next] [New Search]
